Abstract
Background Progressive supranuclear palsy (PSP), a neurodegenerative conditions may be difficult to discriminate clinically from idiopathic Parkinson’s disease (PD). It is critical that we are able to do this accurately and as early as possible in order that future disease modifying therapies for PSP may be deployed at a stage when they are likely to have maximal benefit. Analysis of gait and related tasks is one possible means of discrimination.
Research Question Here we investigate a wearable sensor array coupled with machine learning approaches as a means of disease classification.
Methods 21 participants with PSP, 20 with PD, and 39 healthy control (HC) subjects performed a two minute walk, static sway test, and timed up-and-go task, while wearing an array of six inertial measurement units. The data were analysed to determine what features discriminated PSP from PD and PSP from HC. Two machine learning algorithms were applied, Logistic Regression (LR) and Random Forest (RF).
Results 17 features were identified in the combined dataset that contained independent information. The RF classifier outperformed the LR classifier, and allowed discrimination of PSP from PD with 86% sensitivity and 90% specificity, and PSP from HC with 90% sensitivity and 97% specificity. Using data from the single lumbar sensor only resulted in only a modest reduction in classification accuracy, which could be restored using 3 sensors (lumbar, right arm and foot). However for maximum specificity the full six sensor array was needed.
Significance A wearable sensor array coupled with machine learning methods can accurately discriminate PSP from PD. Choice of array complexity depends on context; for diagnostic purposes a high specificity is needed suggesting the more complete array is advantageous, while for subsequent disease tracking a simpler system may suffice.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov Identifier: NCT04139551
Funding Statement
FUNDING SOURCES FOR THE STUDY: This was study was funded by a grant from the UCB-Oxford Collaboration. JJF and MDV were supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
FINANCIAL DISCLOSURE / CONFLICT OF INTEREST:
MDV, JP,TB, and CAA have no conflicts of interest.
JJF has performed consultancy unrelated to the subject of this study for companies including Abbott, Renishaw, and Herantis, and also has a research grant from Abbott, for a project unrelated to this study.
FUNDING SOURCES FOR THE STUDY:
This was study was funded by a grant from the UCB-Oxford Collaboration. JJF and MDV were supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).
OxQuip is registered on the clinical trials website and this is the CT Identifier: NCT04139551
Data Availability
Anonymised data will be shared by request from any qualified investigator.